HUTCHMED (China) Limited (HK:0013) has released an update.
HUTCHMED (China) Limited has announced that Takeda has received approval from Japan’s Ministry of Health, Labour and Welfare for FRUZAQLA® (fruquintinib), a novel treatment for previously treated metastatic colorectal cancer (CRC). This marks a significant development in Japan’s fight against CRC, which is the most prevalent cancer in the country. With fruquintinib already approved in the US, Europe, and China, the drug’s global data package and its potential to meet a high unmet need for CRC treatment options are underscored.
For further insights into HK:0013 stock, check out TipRanks’ Stock Analysis page.
